PharmaCyte Biotech Reports $8.36 Million Net Loss and Decreased Assets for Quarter Ended July 31, 2025

PharmaCyte Biotech, Inc. reported its financial results for the three months ended July 31, 2025, revealing a significant net loss of $8.36 million, compared to a net income of $23.42 million during the same period in 2024. The company did not generate any revenue in either quarter. Operating expenses decreased to $848,305 from $1.27 million year-over-year, primarily due to reduced general and administrative costs, which fell by 36% to $753,148. Research and development expenses remained relatively stable, totaling $95,157, a slight decrease from $96,016 in the prior year.

The company's total assets decreased to $45.11 million as of July 31, 2025, down from $55.17 million at the end of the previous fiscal period. This decline was attributed to a reduction in cash and cash equivalents, which fell to $13.18 million from $15.17 million. The decrease in total assets was also influenced by a drop in the fair value of investments, particularly in TNF Pharmaceuticals, where the fair value of preferred stock decreased to $19.64 million from $22.47 million. The company’s liabilities also decreased significantly, from $3.28 million to $1.52 million, reflecting a reduction in accrued expenses.

Strategically, PharmaCyte has been focusing on its proprietary Cell-in-a-Box® technology, which is intended for developing therapies for pancreatic cancer. The company has been in discussions with the FDA to lift a clinical hold on its Investigational New Drug Application (IND) for a planned trial in locally advanced pancreatic cancer. The FDA has requested additional studies and data, which the company is currently addressing. In August 2025, PharmaCyte entered into a securities purchase agreement to sell 7,000 shares of newly designated Series C convertible preferred stock, raising $7 million, which is expected to support its operational needs.

Operationally, the company has been reviewing its relationship with SG Austria, the entity that holds the rights to the Cell-in-a-Box technology. The Board of Directors has formed a Business Review Committee to evaluate the company's strategy and operations, which has led to a temporary curtailment of spending on development programs. As of July 31, 2025, PharmaCyte had 6,795,779 shares of common stock outstanding, with no significant changes in customer counts or user statistics reported.

Looking ahead, PharmaCyte anticipates needing additional capital to complete its clinical trial for pancreatic cancer treatment. The company has indicated that any future equity financing may be dilutive to current shareholders, and it is exploring various funding options, including potential collaborations. The ongoing review of its operational strategy and the resolution of the FDA's clinical hold will be critical in determining the company's path forward.